Analystreport

CTI BioPharma Corp. (NASDAQ: CTIC) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $5.50 price target on the stock.

CTI BioPharma Corp.  (CTIC) 
Last cti biopharma corp. earnings: 11/1 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ctibiopharma.com